Promethera raises €39.7mm through Series D round; closes round at €47.2mm
Executive Summary
Promethera Biosciences SA NV raised €39.7mm ($44.4mm) through its Series D round. Itochu Corp. co-led the round with a €10mm investment, along with Shinsei Capital Partners, and the pair were joined by additional buyers Medipal Holdings, Mirae Asset Capital, the family office Six Snow, Korea Investment Partners, Ci:z Investment LLP, Mitsui & Co., and Belgian private investors. Proceeds will support Promethera's HepaStem cell technology platform (liver-derived stem cells from healthy donated organs and expanded in a lab) for acute-on-chronic liver failure (ACLF) and initiation of a clinical trial in NASH.
Update 12/16/2019
| Promethera announced that it received a final closing of €7.5mm ($8.36mm), bringing the Series D total of €47.2mm. New investors Sony Innovation Fund by IGV and Pegasus Tech Ventures led the tranche. New proceeds will be used to advance NASH and acute-on-chronic liver failure candidates, and accelerate the company's growth in Asian markets. |
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice